	PDB	Ligand	Ligand full	HLA	CDR3 seq	CDR3 seq al	TCR contact positions	HLA contact positions	Pep contact positions (TCRbeta)	Pep contact positions (CDR3beta)	Mutations
0	1ao7	LLFGYPVYV	LLFGYPVYV	HLA-A*02:01	CASRPGLAGGRPEQYF	CASR----PGLAGGRPEQYF	1 3 5 6 7 8	1 2 3 5 6 7 8 9	28 92 94 95 96 97 98 99 100	4 6 7 8 9 10 11 12	beta-2 microglobulin
1	1bd2	LLFGYPVYV	LLFGYPVYV	HLA-A*02:01	CASSYPGGGFYEQYF	CASSY-----PGGGFYEQYF	1 5 7 8	1 2 3 5 6 7 8 9	93 94 95 96 97 99	5 6 7 8 9 11	no
2	1lp9	ALWGFFPVL	ALWGFFPVL	HLA-A*02:01	CASSDWVSYEQYF	CASS-------DWVSYEQYF	1 3 5 6 7 8	1 2 3 5 6 7 8 9	31 96 97 98 99	6 7 8 9	no
3	1oga	GILGFVFTL	GILGFVFTL	HLA-A*02:01	CASSSRSSYEQYF	CASS-------SRSSYEQYF	5 6 7 8	2 3 5 6 7 8 9	28 48 49 54 94 95 96	6 7 8	no
4	1qrn	LLFGYAVYV	LLFGYAVYV	HLA-A*02:01	CASRPGLAGGRPEQYF	CASR----PGLAGGRPEQYF	1 5 6 7 8	1 2 3 5 6 7 8 9	28 92 94 95 96 97 98 100	4 6 7 8 9 10 12	no
5	1qse	LLFGYPRYV	LLFGYPRYV	HLA-A*02:01	CASRPGLAGGRPEQYF	CASR----PGLAGGRPEQYF	1 3 5 6 7 8	1 2 3 5 6 7 8 9	28 93 94 95 96 97 98 99 100	5 6 7 8 9 10 11 12	no
6	1qsf	LLFGYPVAV	LLFGYPVAV	HLA-A*02:01	CASRPGLAGGRPEQYF	CASR----PGLAGGRPEQYF	1 3 5 6 7 8	1 2 3 5 6 7 8 9	92 94 95 96 97 98 100	4 6 7 8 9 10 12	no
7	2bnq	SLLMWITQV	SLLMWITQV	HLA-A*02:01	CASSYVGNTGELF	CASSY-------VGNTGELF	4 5 6 7 8	1 2 3 4 6 7 8 9	25 26 27 28 92 93 94 95 96 98	4 5 6 7 8 10	no
8	2bnr	SLLMWITQC	SLLMWITQC	HLA-A*02:01	CASSYVGNTGELF	CASSY-------VGNTGELF	4 5 6 7 8	1 2 3 4 5 6 7 8 9	25 26 27 28 92 93 94 95 96 98	4 5 6 7 8 10	no
9	2f53	SLLMWITQC	SLLMWITQC	HLA-A*02:01	CASSYVGNTGELF	CASSY-------VGNTGELF	4 5 6 7 8	1 2 3 4 5 6 7 8 9	27 28 29 30 94 95 96 97 98 100	4 5 6 7 8 10	beta-2-microglobulin
10	2f54	SLLMWITQC	SLLMWITQC	HLA-A*02:01	CASSYVGNTGELF	CASSY-------VGNTGELF	4 5 6 7 8	1 2 3 4 6 7 8 9	25 26 27 28 92 93 94 95 96 98	4 5 6 7 8 10	cancer/testis antigen 1b
11	2p5e	SLLMWITQC	SLLMWITQC	HLA-A*02:01	CASSYLGNTGELF	CASSY-------LGNTGELF	4 5 6 7 8	1 2 3 4 5 6 7 8 9	25 26 27 28 69 92 93 94 95 96 98	4 5 6 7 8 10	no
12	2p5w	SLLMWITQC	SLLMWITQC	HLA-A*02:01	CASSYLGNTGELF	CASSY-------LGNTGELF	4 5 6 7 8	1 2 3 4 5 6 7 8 9	26 27 28 29 93 94 95 96 97 99	4 5 6 7 8 10	no
13	2pye	SLLMWITQC	SLLMWITQC	HLA-A*02:01	CASSYLGNTGELF	CASSY-------LGNTGELF	4 5 6 7 8	1 2 3 4 5 6 7 8 9	26 27 28 29 94 95 96 97 99	5 6 7 8 10	no
14	2vlk	GILGFVFTL	GILGFVFTL	HLA-A*02:01	CASSSRSSYEQYF	CASS-------SRSSYEQYF	5 6 7 8	2 3 5 6 7 8 9	28 48 49 54 94 95 96	6 7 8	no
15	2vlr	GILGFVFTL	GILGFVFTL	HLA-A*02:01	CASSSRASYEQYF	CASS-------SRASYEQYF	5 6 7 8	2 3 5 6 7 8 9	28 48 49 54 94 95 96	6 7 8	no
16	3gsn	NLVPMVATV	NLVPMVATV	HLA-A*02:01	CASSPVTGGIYGYTF	CASSP-----VTGGIYGYTF	1 3 4 5 7 8 9	1 2 3 4 6 7 8 9	29 95 96 97 98 99	6 7 8 9 10	hla class i histocompatibility antigen, a-2 alpha chain
17	3h9s	MLWGYLQYV	MLWGYLQYV	HLA-A*02:01	CASRPGLAGGRPEQYF	CASR----PGLAGGRPEQYF	1 3 5 6 7 8	1 2 3 5 6 7 8 9	30 96 97 98 99 100 101 102	6 7 8 9 10 11 12	no
18	3o4l	GLCTLVAML	GLCTLVAML	HLA-A*02:01	CSARDGTGNGYTF	CSAR-------DGTGNGYTF	3 4 5 6 7 8	2 3 4 5 6 7 8 9	31 97 98 99 100 101 102	4 5 6 7 8 9	beta-2-microglobulin
19	3pwp	LGYGFVNYI	LGYGFVNYI	HLA-A*02:01	CASRPGLAGGRPEQYF	CASR----PGLAGGRPEQYF	1 3 5 6 7 8	1 3 5 6 7 8 9	30 96 97 98 99 102	6 7 8 9 12	no
20	3qdj	AAGIGILTV	AAGIGILTV	HLA-A*02:01	CASSLSFGTEAF	CASSL--------SFGTEAF	1 4 6 7 8	1 2 4 6 7 8 9	30 51 95 96 97 98	5 6 7 8	no
21	3qeq	AAGIGILTV	AAGIGILTV	HLA-A*02:01	CAISEVGVGQPQHF	CAIS------EVGVGQPQHF	4 6 7 8	1 2 4 6 7 8 9	95 96 97 98 99 100	5 6 7 8 9 10	no
22	3qfj	LLFGFPVYV	LLFGFPVYV	HLA-A*02:01	CASRPGLAGGRPEQYF	CASR----PGLAGGRPEQYF	1 3 5 6 7 8	1 2 3 5 6 7 8 9	30 94 96 97 98 99 100 102	4 6 7 8 9 10 12	tax(y5f) peptide
23	4eup	ALGIGILTV	ALGIGILTV	HLA-A*02:01	CASSFLGTGVEQYF	CASS------FLGTGVEQYF	4 6 7 8	1 2 4 6 7 8 9	28 93 94 95 96 97 98	5 6 7 8 9 10	melanoma antigen recognized by t-cells 1
24	4ftv	LLFGYPVYV	LLFGYPVYV	HLA-A*02:01	CASRPGLMSAQPEQYF	CASR----PGLMSAQPEQYF	1 3 5 6 7 8	1 2 3 5 6 7 8 9	30 94 96 97 98 99 100 101 102	4 6 7 8 9 10 11 12	no
25	4mnq	ILAKFLHWL	ILAKFLHWL	HLA-A*02:01	CASSYQGTEAF	CASS---------YQGTEAF	1 4 5 6 7 8	1 2 3 4 5 6 7 8 9	29 30 49 50 94 95 96	5 6 7	no
26	5d2l	NLVPMVATV	NLVPMVATV	HLA-A*02:01	CASSQTQLWETQYF	CASS------QTQLWETQYF	1 3 4 5 7 8	1 2 3 4 5 6 7 8 9	48 93 94 95 96	6 7 8 9	no
27	5d2n	NLVPMVATV	NLVPMVATV	HLA-A*02:01	CASSLAPGTTNEKLF	CASSL-----APGTTNEKLF	3 4 5 6 7 8	1 2 3 4 5 6 7 8 9	97 98 99 100 101 102 103	6 7 8 9 10 11 12	no
28	5e6i	GILGFVFTL	GILGFVFTL	HLA-A*02:01	CASSLIYPGELF	CASSL--------IYPGELF	3 5 6 7 8	2 3 5 6 7 8 9	48 49 93 94 95	5 6 7	no
29	5eu6	YLEPGPVTV	YLEPGPVTV	HLA-A*02:01	CASSFIGGTDTQYF	CASS------FIGGTDTQYF	1 3 4 6 7 8	1 2 3 4 6 7 8 9	30 48 50 96 97 98 99 100	5 6 7 8 9	no
30	5euo	GILGFVFTL	GILGFVFTL	HLA-A*02:01	CASSIRSSYEQYF	CASS-------IRSSYEQYF	3 5 6 7 8	2 3 5 6 7 8 9	28 48 49 54 93 94 95 96	5 6 7 8	no
31	5hhm	GILGLVFTL	GILGLVFTL	HLA-A*02:01	CASSSRSSYEQYF	CASS-------SRSSYEQYF	5 6 7 8	2 3 5 6 7 8 9	29 49 50 55 70 95 96 97	6 7 8	no
32	5hho	GILEFVFTL	GILEFVFTL	HLA-A*02:01	CASSIRSSYEQYF	CASS-------IRSSYEQYF	4 5 6 7 8	2 3 4 5 6 7 8 9	29 49 50 55 94 95 96 97	5 6 7 8	no
33	5isz	GILGFVFTL	GILGFVFTL	HLA-A*02:01	CASSIFGQREQYF	CASS-------IFGQREQYF	1 2 3 4 5 6 7 8	1 2 3 4 5 6 7 8 9	30 50 51 71 95 96 97 98	5 6 7 8	no
34	5jhd	GILGFVFTL	GILGFVFTL	HLA-A*02:01	CASSIGVYGYTF	CASS--------IGVYGYTF	3 4 5 6 7 8	1 2 3 4 5 6 7 8 9	29 30 49 50 53 70 94 95 96	5 6 7	no
35	5men	ILAKFLHWL	ILAKFLHWL	HLA-A*02:01	CASSYQGTEAF	CASS---------YQGTEAF	1 4 5 6 7 8	1 2 3 4 5 6 7 8 9	29 30 49 50 53 95 96	6 7	no
36	5nme	SLYNTVATL	SLYNTVATL	HLA-A*02:01	CASSDTVSYEQYF	CASS-------DTVSYEQYF	1 3 4 5 6 7 8	1 2 3 4 5 6 7 8 9	50 96 97 99	6 7 9	no
37	5nmf	SLYNTIATL	SLYNTIATL	HLA-A*02:01	CASSDTVSYEQYF	CASS-------DTVSYEQYF	1 3 4 5 6 7 8	1 2 3 4 5 6 7 8 9	49 95 96 98	6 7 9	no
38	5nmg	SLFNTIAVL	SLFNTIAVL	HLA-A*02:01	CASSDTVSYEQYF	CASS-------DTVSYEQYF	1 3 4 5 6 7 8	1 2 3 4 5 6 7 8 9	96 97 99	6 7 9	no
39	5tez	GILGFVFTL	GILGFVFTL	HLA-A*02:01	CASSLLGGWSEAF	CASSL-------LGGWSEAF	5 6 7 8 9	2 3 5 6 7 8 9	28 48 94 95 97	6 7 9	no
40	6eqa	AAGIGILTV	AAGIGILTV	HLA-A*02:01	CAWSETGLGTGELF	CAWS------ETGLGTGELF	2 4 6 7 8	1 2 4 6 7 8 9	95 96 97 98 99 100 101	5 6 7 8 9 10 11	no
41	6eqb	AAGIGILTV	AAGIGILTV	HLA-A*02:01	CAWSETGLGMGGWQF	CAWSE-----TGLGMGGWQF	2 4 6 7 8	1 2 4 6 7 8 9	95 96 97 98 99 100	5 6 7 8 9 10	no
42	4qrr	IPSINVHHY	IPSINVHHY	HLA-B*35:01	CALGELAGAGGTSYGKLTF	CALGEL-AGAGGTSYGKLTF	4 6 7 8	1 2 3 4 5 6 7 8 9	27 29 30 31 94	6	no
43	6bj2	IPLTEEAEL	IPLTEEAEL	HLA-B*35:01	CASSFRGGKTQYF	CASSF-------RGGKTQYF	3 4 5 6 7 8	1 2 3 4 5 6 7 8 9	29 47 49 50 71 94 95 96 98	5 6 7 9	no
44	6bj3	IPLTEEAEL	IPLTEEAEL	HLA-B*35:01	CASRTRGGTLIEQYF	CASR-----TRGGTLIEQYF	1 4 5 7 8	1 2 3 4 5 6 7 8 9	26 28 69 92 93 94 95 96 99	4 5 6 7 8 11	tcr 55 alpha chain
45	6bj8	VPLTEDAEL	VPLTEDAEL	HLA-B*35:01	CASRTRGGTLIEQYF	CASR-----TRGGTLIEQYF	1 4 5 7 8	1 2 3 4 5 6 7 8 9	26 28 69 92 93 94 95 96 99	4 5 6 7 8 11	tcr 55 alpha chain
46	2nx5	LPQGQLTAY	EPLPQGQLTAY	HLA-B*35:01	CATGTGDSNQPQHF	CATG------TGDSNQPQHF	2 5 6 7	0 1 2 3 6 7 8 9	28 29 30 31 94 95 96 97 98 100	4 5 6 7 8 10	no
47	4prp	HPVGQADYF	HPVGQADYFEY	HLA-B*35:01	CASSARSGELF	CASS---------ARSGELF	1 3 6 7 8 9	1 2 3 5 6 8 9 11	28 29 30 31 33 48 50 55 94 95 96	4 5 6	no
48	5xot	IPLTEEAEL	IPLTEEAEL	HLA-B*35:01	CASRTRGGTLIEQYF	CASR-----TRGGTLIEQYF	1 4 5 7 8	1 2 3 4 5 6 7 8 9	28 92 93 94 95 96 99	4 5 6 7 8 11	hla class i histocompatibility antigen, b-35 alpha chain
49	3mv7	HPVGEADYF	HPVGEADYFEY	HLA-B*35:01	CASSARSGELF	CASS---------ARSGELF	1 3 6 7 8 9	1 2 3 5 6 8 9 11	28 29 30 31 33 48 50 55 94 95 96	4 5 6	no
50	3mv8	HPVGEADYF	HPVGEADYFEY	HLA-B*35:01	CASSARSGELF	CASS---------ARSGELF	1 3 6 7 8 9	1 2 3 5 6 8 9 11	29 30 31 32 34 49 50 51 56 95 96 97	4 5 6	no
51	3mv9	HPVGEADYF	HPVGEADYFEY	HLA-B*35:01	CASSARSGELF	CASS---------ARSGELF	1 3 5 6 7 8 9	1 2 3 5 6 8 9 11	28 29 30 31 33 49 50 55 94 95 96	4 5 6	no
52	6vmx	RPPIFIRRL	RPPIFIRRL	HLA-B*07:02	CASSQDLFTGGYTF	CASS------QDLFTGGYTF	1 4 5 6 8	1 2 3 4 5 6 7 8 9	30 51 95 96 97 98 99	5 6 7 8 9	no
53	5c0a	VWGPDPLYV	MVWGPDPLYV	HLA-A*02:01	CASSLWEKLAKNIQYF	CASSL----WEKLAKNIQYF	2 4 5 7 8	1 2 5 6 7 8 9	28 29 46 48 49 95 96	6 7	no
54	5c07	YQFGPDFPI	YQFGPDFPIA	HLA-A*02:01	CASSLWEKLAKNIQYF	CASSL----WEKLAKNIQYF	1 3 5 6 7 8 9	1 2 3 6 7 8 9	30 31 48 50 51 97	6	no
55	5c0b	RQFGPDFPT	RQFGPDFPTI	HLA-A*02:01	CASSLWEKLAKNIQYF	CASSL----WEKLAKNIQYF	1 3 5 6 8 9	1 2 3 5 6 7 8 9	31 32 49 51 52 98	6	no
56	5c09	YLGGPDFPT	YLGGPDFPTI	HLA-A*02:01	CASSLWEKLAKNIQYF	CASSL----WEKLAKNIQYF	1 5 6 7 8 9	1 2 6 7 8 9	28 29 46 48 95	6	no
57	5c08	RQWGPDPAA	RQWGPDPAAV	HLA-A*02:01	CASSLWEKLAKNIQYF	CASSL----WEKLAKNIQYF	1 3 5 6 8	1 2 3 6 7 8 9	29 46 48 95	6	no
58	5hyj	AQWGPDPAA	AQWGPDPAAA	HLA-A*02:01	CASSLWEKLAKNIQYF	CASSL----WEKLAKNIQYF	3 5 6 8	1 2 3 5 6 7 8 9	31 48 50 97	6	no
59	6tmo	AAGIGILTV	EAAGIGILTV	HLA-A*02:01	CAWSETGLGMGGWQF	CAWSE-----TGLGMGGWQF	2 4 6 7 8	1 2 4 6 7 8 9	95 96 97 98 99 100	5 6 7 8 9 10	no
60	5c0c	RQFGPDWIV	RQFGPDWIVA	HLA-A*02:01	CASSLWEKLAKNIQYF	CASSL----WEKLAKNIQYF	1 3 5 6 7 8 9	1 2 3 5 6 7 8 9	31 32 49 51 52 98 99	6 7	no
61	6tro	VYDGREHTV	GVYDGREHTV	HLA-A*02:01	CASSFLMTSGDPYEQYF	CASSF---LMTSGDPYEQYF	3 5 6	1 2 3 5 6 7 8 9	94 95 96 97 98 99 100	7 8 9 10 11 12 13	no
62	6rpb	SLLMWITQV	SLLMWITQV	HLA-A*02:01	CASSYLNRDSALDF	CASSY------LNRDSALDF	4 5 6 7 8	1 2 3 4 5 6 7 8 9	25 26 27 28 93 94 95 96	5 6 7 8	no
63	6rp9	SLLMWITQV	SLLMWITQV	HLA-A*02:01	CASSSPGGVSTEAF	CASS------SPGGVSTEAF	4 6 7 8	1 2 3 4 5 6 7 8 9	30 31 48 50 51 55 96 98 99 100	5 7 8 9	no
64	6rsy	RMFPNAPYL	RMFPNAPYL	HLA-A*02:01	CASSLGFGRDVMRF	CASS------LGFGRDVMRF	1 4 5 7 8	1 2 3 4 5 6 7 8 9	28 29 48 49 94 95 96 97 99	5 6 7 8 10	no
65	7n6e	YLQPRTFLL	YLQPRTFLL	HLA-A*02:01	CAGQVTNTGELF	CAGQ--------VTNTGELF	1 3 4 5 6 7 8	1 2 3 4 5 6 7 8 9	28 48 92 93 94 95 96 97	4 5 6 7 8 9	no
66	6r2l	SLSKILDTV	SLSKILDTV	HLA-A*02:01	CASSPLDVSISSYNEQF	CASSPL--DVSISSYNEQ-F	1 3 4 5 6 7 8	1 2 3 4 5 6 7 8 9	51 97 99 100 101 102 103	7 9 10 11 12 13	no
67	7rtr	YLQPRTFLL	YLQPRTFLL	HLA-A*02:01	CASSPDIEQYF	CASS---------PDIEQYF	1 3 4 5 6 7 8	1 2 3 4 5 6 7 8 9	28 29 48 94 95 96	5 6 7	no
68	5nqk	LAGIGILTV	ELAGIGILTV	HLA-A*02:01	CASSQGLAGAGELF	CASS------QGLAGAGELF	2 4 6 7 8	1 2 4 6 7 8 9	28 49 69 93 94 95 96 97 98	5 6 7 8 9 10	hla class i histocompatibility antigen, a-2 alpha chain
69	5nht	LAGIGILTV	ELAGIGILTV	HLA-A*02:01	CASSQGLAGAGELF	CASS------QGLAGAGELF	2 4 6 7 8	1 2 4 6 7 8 9	28 49 69 93 94 95 97 98	5 6 7 9 10	hla class i histocompatibility antigen, a-2 alpha chain
70	5jzi	LVALGINAV	KLVALGINAV	HLA-A*02:01	CASRRGPYEQYF	CASR--------RGPYEQYF	2 3 4 5 6 7 8 9	1 2 3 4 5 6 7 8 9	30 31 50 51 94 95 96 97	4 5 6 7	no
71	6vqo	HMTEVVRHC	HMTEVVRHC	HLA-A*02:01	CASSIQQGADTQYF	CASS------IQQGADTQYF	4 5 6 7 8	1 2 3 4 5 6 7 8 9	28 48 94 95 97 98	6 7 9 10	peptide from p53 tumor suppressor
72	6vrn	HMTEVVRHC	HMTEVVRHC	HLA-A*02:01	CAISELVTGDSPLHF	CAISE-----LVTGDSPLHF	4 5 6 7 8 9	1 2 3 4 5 6 7 8 9	29 30 49 95 96 97	6 7 8	cellular tumor antigen p53 peptide
73	6vrm	HMTEVVRHC	HMTEVVRHC	HLA-A*02:01	CASSEGLWQVGDEQYF	CASSE----GLWQVGDEQYF	4 5 6 7 8	1 2 3 4 5 6 7 8 9	29 94 95 97 98 99 100 101 102	5 6 8 9 10 11 12 13	cellular tumor antigen p53 peptide
74	6d78	AAGIGILTV	AAGIGILTV	HLA-A*02:01	CASSWSFGTEAF	CASS--------WSFGTEAF	2 4 6 7 8	1 2 4 6 7 8 9	28 49 93 94 95 96 97	5 6 7 8 9	no
75	7n1e	RLQSLQTYV	RLQSLQTYV	HLA-A*02:01	CASSLGGAGGADTQYF	CASSL----GGAGGADTQYF	1 4 5 6 7 8	1 2 3 4 5 6 7 8 9	48 53 95 96 97 98 100	6 7 8 9 11	no
76	7n1f	YLQPRTFLL	YLQPRTFLL	HLA-A*02:01	CASSPDIEQYF	CASS---------PDIEQYF	1 3 4 5 6 7 8	1 2 3 4 5 6 7 8 9	29 30 49 95 96 97	5 6 7	no
77	3qdm	LAGIGILTV	ELAGIGILTV	HLA-A*02:01	CAISEVGVGQPQHF	CAIS------EVGVGQPQHF	4 6 7 8	1 2 4 6 7 8 9	94 95 96 97 98 99	5 6 7 8 9 10	mart-1(27-35) peptide
78	3qdg	LAGIGILTV	ELAGIGILTV	HLA-A*02:01	CASSLSFGTEAF	CASSL--------SFGTEAF	2 4 6 7 8	1 2 4 6 7 8 9	30 51 95 96 97 98 99	5 6 7 8 9	mart-1 (26-35) peptide
79	4l3e	LAGIGILTV	ELAGIGILTV	HLA-A*02:01	CASSWSFGTEAF	CASS--------WSFGTEAF	2 4 6 7 8	1 2 4 6 7 8 9	30 51 95 96 97 98 99	5 6 7 8 9	melanoma antigen recognized by t-cells 1
80	6dkp	LAGIGILTV	ELAGIGILTV	HLA-A*02:01	CASSWSFGTEAF	CASS--------WSFGTEAF	2 4 6 7 8	1 2 4 6 7 8 9	30 51 95 96 97 98 99	5 6 7 8 9	melanoma antigen recognized by t-cells 1
81	5e9d	LAGIGILTV	ELAGIGILTV	HLA-A*02:01	CASRPGWMAGGVELYF	CASR----PGWMAGGVELYF	4 7 8	1 2 4 6 7 8 9	96 97 98 99	7 8 9 10	melanoma derived mart-1 peptide
82	4qok	AAGIGILTV	EAAGIGILTV	HLA-A*02:01	CAWSETGLGTGELF	CAWS------ETGLGTGELF	2 4 6 7 8	1 2 4 6 7 8 9	95 96 97 98 99 100 101	5 6 7 8 9 10 11	no
83	3hg1	LAGIGILTV	ELAGIGILTV	HLA-A*02:01	CAWSETGLGTGELF	CAWS------ETGLGTGELF	2 4 6 7 8	1 2 4 6 7 8 9	96 97 98 99 100 101	6 7 8 9 10 11	no
84	3uts	ALWGPDPAA	ALWGPDPAAA	HLA-A*02:01	CASSLWEKLAKNIQYF	CASSL----WEKLAKNIQYF	1 3 5 6 8	1 2 3 6 7 8 9	31 48 50 97	6	no
85	6am5	MLGIGIVPV	SMLGIGIVPV	HLA-A*02:01	CASSLSFGTEAF	CASSL--------SFGTEAF	2 4 6 7 8	1 2 4 6 7 8 9	30 51 95 96 97 98 99	5 6 7 8 9	no
86	6amu	MMWDRGLGM	MMWDRGLGMM	HLA-A*02:01	CASSLSFGTEAF	CASSL--------SFGTEAF	1 3 4 5	1 2 3 4 5 7 9	95 96 97 98 99	5 6 7 8 9	no
87	6rpa	SLLMWITQV	SLLMWITQV	HLA-A*02:01	CSVGGSGGADTQYF	CSVG------GSGGADTQYF	1 4 5 6 7 8	1 2 3 4 5 6 7 8 9	28 30 97 98 99 100 102	5 6 7 8 10	no
88	7rm4	HMTEVVRHC	HMTEVVRHC	HLA-A*02:01	CALDIYPHDMRF	CALD----------------	4 5 6 7 8	1 2 3 4 5 6 7 8 9	27 28 29 30 91 92 93 94 95	4 5 6 7 8	cellular tumor antigen p53 peptide
